KEGG   DRUG: D02596Help
Entry
D02596                      Drug                                   

Name
Tocilizumab (genetical recombination) (JAN);
Tocilizumab (USAN/INN);
Actemra (TN)
Product
Formula
C6428H9976N1720O2018S42
Exact mass
144895.9145
Mol weight
144985.0322
Activity
Treatmet of Castelman's disease;
Treatment of multiple myeloma;
Treatment of systemic lupus erythematosus;
Treatment of Crohs's disease;
Treatment of rheumatoid arthritis;
Treatment of systemic juvenile idiopathic arthritis [DS:H00630]
Remark
Therapeutic category: 
ATC code: 
Comment
humanized monoclonal antybody
Target
interleukin-6 (IL-6) receptor [HSA:3570] [KO:K05055]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  Jak-STAT signaling pathway
hsa04640  Hematopoietic cell lineage  
 
Interaction
Drug interaction
Structure map
Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC07 Tocilizumab
      D02596  Tocilizumab (genetical recombination) (JAN); Tocilizumab (USAN/INN)
USP drug classification [BR:br08302]
 Immunological Agents
  Immunomodulators
   Tocilizumab
    D02596  Tocilizumab (genetical recombination) (JAN); Tocilizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D02596  Tocilizumab (genetical recombination) (JAN); Tocilizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Class I cytokine receptors (hematopoietin family receptors)
   interleukin 6 receptor
    Tocilizumab
     D02596  Tocilizumab (genetical recombination) (JAN); Tocilizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
375823-41-9
PubChem: 
NIKKAJI: 

» Japanese version   » Back

DBGET integrated database retrieval system